Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.

Transactions / LifeSpan Biosciences, Inc.

Thompson Street Capital Partners Acquires LifeSpan Biosciences, Inc.

Platform acquisitionannouncedannounced Sep 17, 2018Fact
What happened
Target
LifeSpan Biosciences, Inc.
Platform
not an add-on on record
Control
Control
Share acquired
unknown
Industry
unknown
Target location
unknown
Seller kind
Founder
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
3 named
Buy side
  • Robert Charles DunnDeal partnerconfirmed
    “Bob Dunn, a Managing Director and Head of Acquisitions at TSCP, said, “We’re excited to be partnering with the founders of LSBio.”
  • Thompson Street Capital Manager LLCSponsorconfirmed
    “Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, has partnered with management to acquire Seattle-based LifeSpan Biosciences, Inc., (LSBio).”
Side not stated
Evidence
“Thompson Street Capital Partners Acquires LifeSpan Biosciences, Inc.”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 15, 2026
Thompson Street Capital Partners Acquires LifeSpan Biosciences, Inc. | Private Equity Intelligence | DFX